

# Cyrill A Rentsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6264732/publications.pdf>

Version: 2024-02-01

31  
papers

1,021  
citations

623734

14  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1704  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer. <i>Science Translational Medicine</i> , 2012, 4, 137ra72.	12.4	216
2	ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2916-2929.	8.2	176
3	Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy. <i>European Urology</i> , 2014, 66, 677-688.	1.9	164
4	The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. <i>Frontiers in Immunology</i> , 2017, 8, 1147.	4.8	133
5	Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. <i>Journal of Pathology</i> , 2021, 254, 543-555.	4.5	35
6	Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus. <i>Journal of Pathology</i> , 2018, 244, 265-270.	4.5	34
7	Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept. <i>Diagnostics</i> , 2020, 10, 951.	2.6	33
8	Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?. <i>European Urology</i> , 2017, 72, 960-961.	1.9	32
9	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 51-60.	2.2	31
10	Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. <i>Oncolmmunology</i> , 2020, 9, 1748981.	4.6	19
11	Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. <i>Journal of Pathology</i> , 2018, 245, 74-84.	4.5	18
12	Patterns of stemness-associated markers in the development of castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 1108-1117.	2.3	17
13	Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. <i>Cancer Cytopathology</i> , 2019, 127, 578-585.	2.4	16
14	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. <i>Oncotarget</i> , 2017, 8, 7964-7976.	1.8	16
15	BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model. <i>PLoS ONE</i> , 2013, 8, e56327.	2.5	15
16	Dynamics of Urinary Calprotectin after Renal Ischaemia. <i>PLoS ONE</i> , 2016, 11, e0146395.	2.5	11
17	A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. <i>European Urology Oncology</i> , 2022, , .	5.4	10
18	Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy. <i>European Urology Focus</i> , 2018, 4, 485-493.	3.1	9

#	ARTICLE	IF	CITATIONS
19	The Importance of Standardised Recording of Intraoperative Adverse Events: Key Features of an Ideal Classification System. <i>European Urology</i> , 2020, 77, 611-613.	1.9	6
20	Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2016, 34, 162-162.	1.6	6
21	Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. <i>European Urology Oncology</i> , 2022, 5, 677-686.	5.4	6
22	Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e151-e159.	1.9	4
23	High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores. <i>Pathobiology</i> , 2022, 89, 74-80.	3.8	4
24	Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep. <i>European Urology</i> , 2015, 68, 968-969.	1.9	3
25	Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer. <i>European Urology</i> , 2016, 70, 83-84.	1.9	3
26	Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies. <i>Urologia Internationalis</i> , 2022, 106, 83-89.	1.3	2
27	Enhancing disease awareness for tuberous sclerosis complex in patients with radiologic diagnosis of renal angiomyolipoma: an observational study. <i>BMC Nephrology</i> , 2021, 22, 47.	1.8	2
28	Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer. <i>Lancet Oncology</i> , The, 2021, 22, e379.	10.7	0
29	Influence of Different Components of the Tumor Microenvironment on Human Patient-Derived Lymphoma Cell Engraftment in Immunodeficient Mice. <i>Blood</i> , 2015, 126, 1459-1459.	1.4	0
30	Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study. <i>European Urology</i> , 2022, 81, 542.	1.9	0
31	Abstract 3073: Bladder cancer patient-derived organoids to decipher cellular plasticity and cancer progression. <i>Cancer Research</i> , 2022, 82, 3073-3073.	0.9	0